Current and emerging pharmacotherapy for the treatment of bacterial peritonitis

References

• Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383:1749–1761.
   PubMed Web of Science ®Google Scholar
• Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258–266.
   PubMed Web of Science ®Google Scholar
• Acevedo JG, Cramp ME. Hepatorenal syndrome: update on diagnosis and therapy. World J Hepatol. 2017;9:293–299.
   PubMed Web of Science ®Google Scholar
• Gentile I, Viola C, Graf M, et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol. 2009;43:81–87.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Scotto R, et al. Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage. Eur J Intern Med. 2017;46:e45–e47.
   PubMed Web of Science ®Google Scholar
• Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139:1246–1256.
   PubMed Web of Science ®Google Scholar
• Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL special conference 2013. J Hepatol. 2014;60:1310–1324.
   PubMed Web of Science ®Google Scholar
• Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(Suppl 1):1–12.
   PubMedGoogle Scholar
• Bartoletti M, Giannella M, Lewis R, et al. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clin Microbiol Infect. 2017;24:546.e1–546.e8.
   PubMed Web of Science ®Google Scholar
• Piano S, Bartoletti M, Tonon M, et al. Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. Gut. 2017;gutjnl-2017–314324. [Epub ahead of print]. doi:10.1136/gutjnl-2017-314324
   PubMedGoogle Scholar
• Maraolo AE, Giacobbe DR, Fiore M. The diagnostic conundrum of bacterial infections in cirrhotic patients. Liver Int. 2017;37:1411.
   PubMed Web of Science ®Google Scholar
• Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut. 2005;54:718–725.
   PubMed Web of Science ®Google Scholar
• Dionigi E, Garcovich M, Borzio M, et al. Bacterial infections change natural history of cirrhosis irrespective of liver disease severity. Am J Gastroenterol. 2017;112:588–596.
   PubMed Web of Science ®Google Scholar
• Kuiper JJ, De Man RA, Van Buuren HR. Review article management of ascites and associated complications in patients with cirrhosis. Aliment Pharmacol Ther. 2007;26(Suppl 2):183–193.
   PubMedGoogle Scholar
• Mowat C, Stanley AJ. Review article: spontaneous bacterial peritonitis–diagnosis, treatment and prevention. Aliment Pharmacol Ther. 2001;15:1851–1859.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.
   PubMed Web of Science ®Google Scholar
• Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin–tobramycin in cirrhotics with severe infections. Hepatology. 1985;5:457–462.
   PubMed Web of Science ®Google Scholar
• Rimola A, Salmerón JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology. 1995;21:674–679.
   PubMed Web of Science ®Google Scholar
• Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology. 1996;111:1011–1017.
   PubMed Web of Science ®Google Scholar
• Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409.
   PubMed Web of Science ®Google Scholar
• Ricart E, Soriano G, Novella MT, et al. Amoxicillin–clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol. 2000;32:596–602.
   PubMed Web of Science ®Google Scholar
• Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087–2107.
   PubMed Web of Science ®Google Scholar
• Fagiuoli S, Colli A, Bruno R, et al. Management of infections in cirrhotic patients: report of a consensus conference. Dig Liver Dis. 2014;46:204–212.
   PubMedGoogle Scholar
• Lutz P, Nischalke HD, Strassburg CP, et al. Spontaneous bacterial peritonitis: the clinical challenge of a leaky gut and a cirrhotic liver. World J Hepatol. 2015;7:304–314.
   PubMed Web of Science ®Google Scholar
• Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am. 1995;79:705–719.
   PubMed Web of Science ®Google Scholar
• Van De Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22(Suppl 3):37–62.
   PubMed Web of Science ®Google Scholar
• Piccirilli G, Chiereghin A, Gabrielli L, et al. Infectious meningitis/encephalitis: evaluation of a rapid and fully automated multiplex PCR in the microbiological diagnostic workup. New Microbiol. 2018;41:118–125.
   PubMed Web of Science ®Google Scholar
• Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014;371:1619–1628.
   PubMed Web of Science ®Google Scholar
• Iredell J, Brown J, Tagg K, et al. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. BMJ. 2016;352:h6420.
   PubMed Web of Science ®Google Scholar
• Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: a critical review and practical guidance. World J Hepatol. 2016;8:307–321.
   PubMed Web of Science ®Google Scholar
• PLOS Medicine Editors. Antimicrobial resistance: is the world unprepared?. PLoS Med. 2016;13:e1002130.
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
   PubMed Web of Science ®Google Scholar
• Acevedo J. Multiresistant bacterial infections in liver cirrhosis: clinical impact and new empirical antibiotic treatment policies. World J Hepatol. 2015;7:916–921.
   PubMed Web of Science ®Google Scholar
• Merli M, Lucidi C, Di Gregorio V, et al. The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey. PLoS One. 2015;10:e0127448.
   PubMed Web of Science ®Google Scholar
• Fiore M, Maraolo AE, Gentile I. Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis. World J Hepatol. 2017;9:1166–1175.
   PubMed Web of Science ®Google Scholar
• Paul M, Zemer-Wassercug N, Talker O, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?. Clin Microbiol Infect. 2011;17:1581–1586.
   PubMed Web of Science ®Google Scholar
• Fernández J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551–1561.
   PubMed Web of Science ®Google Scholar
• Salerno F, Borzio M, Pedicino C, et al. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. Liver Int. 2017;37:71–79.
   PubMed Web of Science ®Google Scholar
• Heo J, Seo YS, Yim HJ, et al. Clinical features and prognosis of spontaneous bacterial peritonitis in Korean patients with liver cirrhosis: a multicenter retrospective study. Gut Liver. 2009;3:197–204.
   PubMed Web of Science ®Google Scholar
• Heong HS, Kang CI, Lee JA, et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis. 2009;48:1230–1236.
   PubMed Web of Science ®Google Scholar
• Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis–bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther. 2015;41:1116–1131.
   PubMed Web of Science ®Google Scholar
• Gaetano JN, Micic D, Aronsohn A, et al. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016;31:1025–1030.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Tsukamoto MM, Mathur AK, et al. Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis. Am J Gastroenterol. 2014;109:1436–1442.
   PubMed Web of Science ®Google Scholar
• Fiore M, Maraolo AE, Leone S, et al. Spontaneous peritonitis in critically ill cirrhotic patients: a diagnostic algorithm for clinicians and future perspectives. Ther Clin Risk Manag. 2017;13:1409–1414.
   PubMed Web of Science ®Google Scholar
• Karvellas CJ, Abraldes JG, Arabi YM, et al. Appropriate and timely antimicrobial therapy in cirrhotic patients with spontaneous bacterial peritonitis-associated septic shock: a retrospective cohort study. Aliment Pharmacol Ther. 2015;41:747–757.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2016. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2017 cited 2018 May 29. Available from: https://ecdc.europa.eu/sites/portal/files/documents/AMR-surveillance-Europe-2016.pdf
   Google Scholar
• Friedrich K, Nüssle S, Rehlen T, et al. Microbiology and resistance in first episodes of spontaneous bacterial peritonitis: implications for management and prognosis. J Gastroenterol Hepatol. 2016;31:1191–1195.
   PubMed Web of Science ®Google Scholar
• Carey W, Boayke A, Leatherman J. Spontaneous bacterial peritonitis, clinical and laboratory features with reference to hospital-acquired cases. Am J Gastroenterol. 1986;81:1156–1161.
   PubMed Web of Science ®Google Scholar
• Ogurick AG, Intagliata NM. Management of nosocomial spontaneous bacterial peritonitis: a complex and moving target. Clin Liv Dis. 2017;10:144–147.
   Google Scholar
• Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol. 2010;8:979–985.
   PubMed Web of Science ®Google Scholar
• Venditti M, Falcone M, Corrao S, et al. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital acquired pneumonia. Ann Intern Med. 2009;150:19–26.
   PubMed Web of Science ®Google Scholar
• Metersky ML, Kalil AC. New guidelines for nosocomial pneumonia. Curr Opin Pulm Med. 2017;23:211–217.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:61–111.
   PubMed Web of Science ®Google Scholar
• Lutz P, Nischalke HD, Krämer B, et al. Antibiotic resistance in healthcare-related and nosocomial spontaneous bacterial peritonitis. Eur J Clin Invest. 2017;47:44–52.
   PubMed Web of Science ®Google Scholar
• Titó L, Rimola A, Ginès P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology. 1988;8:27–31.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Dig Dis. 2016;34:382–386.
   PubMed Web of Science ®Google Scholar
• Merli M, Lucidi C, Di Gregorio V, et al. An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: a randomized trial. Hepatology. 2016;63:1632–1639.
   PubMed Web of Science ®Google Scholar
• Piano S, Fasolato S, Salinas F, et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial. Hepatology. 2016;63:1299–1309.
   PubMed Web of Science ®Google Scholar
• Fiore M, Maraolo AE, Gentile I, et al. Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: a systematic review. World J Gastroenterol. 2017;23:4654–4660.
   PubMed Web of Science ®Google Scholar
• Fiore M, Gentile I, Maraolo AE, et al. Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:329–336.
   PubMed Web of Science ®Google Scholar
• Runyon BA. AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57:1651–1653.
   PubMed Web of Science ®Google Scholar
• Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60:1310–1324.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018; [Epub ahead of print]. DOI:10.1016/j.jhep.2018.03.024
   Web of Science ®Google Scholar
• Ison MG. Empiric treatment of nosocomial spontaneous bacterial peritonitis: one size does not fit all. Hepatology. 2016;63:1083–1085.
   PubMed Web of Science ®Google Scholar
• Viceconte G, Maraolo AE, Iula VD, et al. Appropriateness of antibiotic prescription for targeted therapy of infections caused by multidrug-resistant bacteria: assessment of the most common improper uses in a tertiary hospital in southern Italy. Infez Med. 2017;25:224–233.
   PubMedGoogle Scholar
• Bell BG, Schellevis F, Stobberingh E, et al. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14:13.
   PubMed Web of Science ®Google Scholar
• Schoonover LL, Occhipinti DJ, Rodvold KA, et al. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination. Ann Pharmacother. 1995;29:501–514.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, et al. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31:e00079-17.
   Web of Science ®Google Scholar
• Papp-Wallace KM, Endimiani A, Taracila MA, et al. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55:4943–4960.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Del Bono V, Bruzzi P, et al. Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant Klebsiella pneumoniae bacteraemia in colonized patients: results from a retrospective multicentre study. Eur J Clin Microbiol Infect Dis. 2017;36:663–669.
   PubMed Web of Science ®Google Scholar
• Van Loon K, Voor AF, Vos MC. A systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;62(1).
   PubMed Web of Science ®Google Scholar
• Martirosov DM, Lodise TP. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016;85:266–275.
   PubMed Web of Science ®Google Scholar
• Bruniera FR, Ferreira FM, Saviolli LR, et al. The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci. 2015;19:694–700.
   PubMed Web of Science ®Google Scholar
• Nicolaou KC, Mitchell HJ, Jain NF, et al. Total synthesis of vancomycin. Angew. Chem. 1999;111:249–253.
   Google Scholar
• Ye ZK, Chen YL, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71:3020–3025.
   PubMed Web of Science ®Google Scholar
• Baltz RH. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol. 2009;13:144–151.
   PubMed Web of Science ®Google Scholar
• Lam HY, Zhang Y, Liu H, et al. Total synthesis of daptomycin by cyclization via a chemoselective serine ligation. J Am Chem Soc. 2013;135:6272–6279.
   PubMed Web of Science ®Google Scholar
• Barber KE, King ST, Stover KR, et al. Therapeutic options for vancomycin-resistant enterococcal bacteremia. Expert Rev Anti Infect Ther. 2015;13:363–377.
   PubMed Web of Science ®Google Scholar
• Roger C, Roberts JA, Muller L. Clinical pharmacokinetics and pharmacodynamics of oxazolidinones. Clin Pharmacokinet. 2018;57:559–575.
   PubMed Web of Science ®Google Scholar
• Fernández J, Acevedo J. New antibiotic strategies in patients with cirrhosis and bacterial infection. Expert Rev Gastroenterol Hepatol. 2015;9:1495–1500.
   PubMed Web of Science ®Google Scholar
• Maraolo AE, Cascella M, Corcione S, et al. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art. Expert Rev Anti Infect Ther. 2017;15:861–871.
   PubMed Web of Science ®Google Scholar
• Sharma R, Park TE, Moy S. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination for the treatment of resistant Gram-negative organisms. Clin Ther. 2016;38:431–444.
   PubMed Web of Science ®Google Scholar
• Gentile I, Maraolo AE, Borgia G. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?. Expert Rev Anti Infect Ther. 2016;14:875–878.
   PubMed Web of Science ®Google Scholar
• De Waele JJ, Akova M, Antonelli M, et al. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Med. 2018;44:189–196.
   PubMed Web of Science ®Google Scholar
• Abbas M, Paul M, Huttner A. New and improved? A review of novel antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2017;23:697–703.
   PubMed Web of Science ®Google Scholar
• Cardoso T, Almeida M, Friedman ND, et al. Classification of healthcare-associated infection: a systematic review 10 years after the first proposal. BMC Med. 2014;12:40.
   PubMed Web of Science ®Google Scholar